Device Trial Radar · NCT06895187
Catheter Ablation Using a Novel Navigation and Imaging System
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 1, 2027
Primary completion
Dec 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- LUMA Vision Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 26, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the ENVIsIoN study is to collect data on the use of the VERAFEYE navigation and imaging system in patients indicated to undergo a catheter ablation procedure for the treatment of Paroxysmal Atrial Fibrillation (PAF).
Conditions
- Paroxysmal Atrial Fibrillation
Interventions
VERAFEYE SystemDevice
VERAFEYE system guidance will be used on all patients undergoing PAF ablation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acute procedural success rates during the index procedureTime frame: During the procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.